ALL BLOGS BY

Emily Dwyer

Emily provides broad paralegal services including litigation support services, legal research, IP monitoring and tracking services, and document management. A self professed “legal junkie” she loves exploring legal arguments and is excited about new legal developments.

See Emily's full profile

BioBlast® w/e 8 July 2022: featuring Xbrane’s ranibizumab BLA, Viatris’ insulin glargine, Alvotech’s aflibercept study and AU’s July PBAC meeting

by Naomi Pearce, Emily Dwyer | Jul 11, 2022

04 Jul 22 | US | Xbrane Biopharma provides update on ranibizumab biosimilar Xbrane Biopharma confirmed that it will...

BioBlast® w/e 01 July 22: Samsung seeks to revoke Fresenius’ AU adalimumab patent, Daiichi Sankyo’s trastuzumab deruxtecan sNDA submitted in Japan, PDS0101 Fast-tracked in US, Henlius HLX53 IND accepted

by Naomi Pearce, Emily Dwyer | Jul 4, 2022

24 Jun 22 | AU | Samsung Bioepis commences AU revocation action against Fresenius Kabi adalimumab patent Samsung...

BioBlast® w/e 24 Jun 22: Alvotech dual NASDAQ listing, Samsung Bioepis/Samil ranibizumab, Formycon Q1/22 results, Daiichi Sankyo trastuzumab deruxtecan, Midas Pharma’s ranibizumab, Celltrion’s bevacizumab, Merck’s pembrolizumab, AVEO/Eli Lilly agreement, Innovent’s sintilimab

by Naomi Pearce, Emily Dwyer | Jun 27, 2022

20 Jun 22 | CN | NMPA approves Innovent’s TYVYT® (sintilimab injection) Innovent Biologics and Eli Lilly announced...

BioBlast® w/e 17 Jun 22: featuring Alvotech’s NASDAQ listing, Samsung Bioepis’ eculizumab, Organon/Henlius’ global biosimilars deal, Sandoz’s citrate-free adalimumab and Innovent’s bevacizumab

by Naomi Pearce, Emily Dwyer | Jun 20, 2022

11 Jun 22 | Samsung Bioepis presents Ph III eculizumab data Samsung Bioepis presented data from its Ph III trials of...

BioBlast® w/e 10 June 2022: featuring Alvotech/Stada’s adalimumab, Amgen’s rituximab, Fresenius’ tocilizumab IPR, dostarlimab study and Civica’s insulin

by Naomi Pearce, Emily Dwyer | Jun 15, 2022

02 Jun 22 | Civica selects Profil as clinical trial partner for affordable insulin initiative Civica announced that is...

BioBlast® w/e 03 June 2022: featuring Outlook’s bevacizumab, Lannett’s insulin glargine, Henlius’ biosims, Novartis’ brolucizumab, Roche’s faricimab, Biogen/Samsung Byooviz™ & GBMA Biosimilars Awareness Week

by Naomi Pearce, Emily Dwyer | Jun 6, 2022

24 May 22 | BR | Shanghai Henlius Biotech signs license agreement for rituximab and trastuzumab biosims Shanghai...

BioBlast® w/e 27 May 22 : Prestige’s trastuzumab rejected by CHMP; Additional EU indications for Merck’s Keytruda; Jury trial set in BMS/AstraZeneca patent infringement suit re durvalumab; First patients dosed in Biond Biologics trials for BND-22 (SAR444881); FDA approves Amneal’s Fylnetra™ (biosimilar pegfilgrastim).. and more

by Naomi Pearce, Emily Dwyer | May 30, 2022

20 May 22 | EU | Prestige Biopharma (Roche/Genentech) | HD201, trastuzumab (Herceptin®) Prestige’s trastuzumab...

BioBlast® w/e 20 May 22: Alvotech’s biosim ustekinumab study results, Samsung Bioepis’ biosim ranibizumab approved in KR, Teva/BioEq’s biosim ranibizumab approved in the UK; Celltrion’s PhIII clinical trial for tocilizumab biosim

by Naomi Pearce, Emily Dwyer | May 25, 2022

16 May 22 | Alvotech (Janssen) | AVT04, ustekinumab, (Stelara®)Alvotech announces study results for AVT04, biosimilar...

Pearce IP BioBlast® w/e 13 May 2022

by Naomi Pearce, Emily Dwyer | May 17, 2022

04 May 22 | Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal...

Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways

by Kate Legge, Emily Dwyer, Naomi Pearce | May 10, 2022

Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...

Pearce IP BioBlast® w/e 06 May 2022

by Naomi Pearce, Emily Dwyer | May 9, 2022

29 Apr 22 | Merck announced that the EC has approved Keytruda® (pembrolizumab) in combination with chemotherapy (with...

Psychedelic Medicines Part 1

Patenting known and new chemical entities

by Naomi Pearce, Emily Dwyer | May 4, 2022

Depression, anxiety and related disorders are serious conditions whose treatment is - in many cases - not adequately...

Medicinal Cannabis in Australia | Part 1: Available Products

« Older Entries

Next Entries »